G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score
Women Infertility
About this trial
This is an interventional supportive care trial for Women Infertility focused on measuring IVF
Eligibility Criteria
Inclusion Criteria:
- ALL Women aged < 40 years who would be submitted to oocyte retrieval and embryo transfer IN IVF cycle.
Exclusion Criteria:
- • contraindications for G-CSF treatment (sickle cell disease, chronic neutropenia, known past or present malignancy, renal insufficiency, upper respiratory infection, pneumonia, and congenital fructose intolerance)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Experimental
Sham Comparator
Placebo
G-CSF group
Comparative group
Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before. The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer
patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only